Tel. +41 61 295 50 00info@baselarea. swiss
The Basel-based IT company Genedata, which specializes in supplying software solutions to the biopharmaceutical industry, has expanded its partnership with Boehringer Ingelheim. Genedata will now be digitalizing and automating cell line development processes for the pharma group.
Cell lines are cells that are cultivated and which can be reproduced infinitely. In this context, for example, drugs based on antibodies or proteins can be manufactured. The German pharmaceutical company Boehringer Ingelheim, which is based in Basel via Boehringer Ingelheim (Schweiz) GmbH, is also active in the area of cell line development. In this context, the company is now being supported by the Basel IT firm Genedata, as revealed in a press release.
To this end, Genedata will be digitalizing and automating processes within the scope of cell line development projects at Boehringer Ingelheim, for which a pre-existing cooperation agreement is being expanded. Genedata will align and automate processes based on what is known as next-generation sequencing (NGS). This is a sequencing process in which extremely large volumes of sample fragments are sequenced simultaneously. In order to standardize and automate these NGS processes, Genedata will provide a platform for data management and analysis. This solution is to be based on the Genedata Selector software developed by the Basel-based company.
“Genedata is committed to supporting our customers looking to automate and digitalize their bioproduction processes by providing the most advanced and innovative technologies for organizations to maximize their return”, commented Othmar Pfannes, Ph.D., CEO of Genedata, in the press release.